Adipotide, also known as FTPP, is an experimental weight loss treatment that kills fat cells by targeting the blood supply of those cells.

ARA-290 is variant of erythropoietin which has been shown to decrease inflammatory pathways through paracrine signalling and the innate repair receptors. Research has shown ARA-290 to help reduce HbA1c, improve cholesterol, modulate neuropathic pain and stimulate wound repair.

  Orforglipron (LY3502970, OWL833) is a highly orally bioavailable small-molecule partial activator of the GLP-1 receptor. Through G-protein–coupled pathways, it replicates incretin effects while maintaining receptor sensitivity. Studies show it promotes improved body composition, metabolic balance, better glucose control, and enhanced beta-cell protection. It also helps balance cholesterol and inflammatory markers, contributing to cardiovascular and metabolic wellness. These findings suggest Orforglipron may play an important role in supporting overall metabolic efficiency and cellular resilience.